Fibrolamellar Hepatocellular Carcinoma: Treatment with Yttrium-90 and Subsequent Surgical Resection

Journal Article · Tue May 15 00:00:00 EDT 2018 · Cardiovascular and Interventional Radiology

DOI:https://doi.org/10.1007/S00270-018-1903-6· OSTI ID:22750027

Mafeld, Sebastian ^[1]; French, Jeremy ^[2]; Tiniakos, Dina ^[3]; Haugk, Beate ^[4]; Manas, Derek ^[2]; Littler, Peter ^[1]

---

1. Freeman Hospital, Department of Interventional Radiology (United Kingdom)
2. Freeman Hospital, Department of Hepatobiliary Surgery (United Kingdom)
3. Newcastle University, Institute of Cellular Medicine, Faculty of Medical Sciences (United Kingdom)
4. Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Department of Cellular Pathology (United Kingdom)

We describe a 52-year-old female patient who presented with a 9.5-cm fibrolamellar hepatocellular carcinoma (FL-HCC). The patient was initially unsuitable for surgical resection and therefore underwent transarterial chemoembolization followed by selective internal radiation therapy (SIRT) with Yttrium-90 to downsize the tumour. Following SIRT, the tumour decreased in volume from 350 to 20 cm{sup 3} allowing curative (R0) resection with an extended left hepatectomy and reconstruction of IVC. This is the first reported case of FL-HCC treated with SIRT in which, due to the good SIRT response, the patient was downsized to allow curative resection.

• OSTI ID: 22750027
• Journal Information: Cardiovascular and Interventional Radiology, Vol. 41, Issue 5; Other Information: Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); Article Copyright (c) 2018 The Author(s); http://www.springer-ny.com; Country of input: International Atomic Energy Agency (IAEA); ISSN 0174-1551
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
HEPATOMAS
PATIENTS
YTTRIUM 90